Exploration of a Sequential Gp140-Gp145 Immunization Regimen with Heterologous Envs to Induce a Protective Cross-Reactive HIV Neutralizing Antibody Response In Non-human Primates

Posted on by Erik Young
Exploration of a Sequential Gp140-Gp145 Immunization Regimen with Heterologous Envs to Induce a Protective Cross-Reactive HIV Neutralizing Antibody Response In Non-human Primates

Raising a heterologous tier 2 neutralizing antibody (nAb) response stays a daunting job for HIV vaccine growth. In this research, we explored the utility of numerous HIV-1 envelope (Env) immunogens in a sequential immunization scheme as a answer to this job. This exploration stemmed from the rationale that gp145, a membrane-bound truncation kind of HIV Env, could facilitate the focusing of induced antibody response on neutralizing epitopes when sequentially mixed with the soluble gp140 kind as immunogens in a prime-boost mode. We first confirmed that gp140 DNA prime-gp145 Tiantan vaccinia (TV) enhance probably represents a common format for inducing potent nAb response in mice.

However, when examined in rhesus macaque, this modality confirmed little effectiveness. To enhance the efficacy, we prolonged the unique modality by including a robust protein enhance, particularly native-like SOSIP.664 trimer displayed on ferritin-based nanoparticle (NP), which was generated by a newly developed click on method. The ensuing three-immunization routine succeeded in eliciting tier-2 nAb response with substantial breadth when carried out in rhesus macaque over a brief 8-week schedule. Importantly, the elicited nAb response was in a position to successfully comprise viremia upon a heterologous SHIV problem. Collectively, our research highlighted that diversification of Env immunogens, in each varieties and formulations, underneath the framework of a sequential immunization scheme would possibly open new alternative towards HIV vaccine growth.

An efficacious HIV-1 vaccine has remained an elusive goal for nearly 40 years. The sheer variety of the virus is one of the most important roadblocks for vaccine growth. HIV-1 often mutates and numerous strains predominate in numerous geographic areas, making the event of a globally relevant vaccine extraordinarily troublesome. Multiple approaches have been taken to overcome the problem of viral variety, together with sequence optimization, growth of consensus and mosaic sequences and the use of totally different prime-boost approaches. To develop an efficacious vaccine, these approaches may have to be mixed. One method to probably synergize these approaches is to use a rationally designed protein nanoparticle that enables for the native-like presentation of antigens, such because the self-assembling protein nanoparticle.

Parainfluenza Virus 5 Priming Followed by SIV/HIV Virus-Like-Particle Boosting Induces Potent and Durable Immune Responses in Nonhuman Primates

The seek for a preventive vaccine towards HIV an infection stays an ongoing problem, indicating the necessity for novel approaches. Parainfluenza virus 5 (PIV5) is a paramyxovirus replicating within the higher airways that isn’t related with any animal or human pathology. In animal fashions, PIV5-vectored vaccines have proven safety towards influenza, RSV, and different human pathogens. Here, we generated PIV5 vaccines expressing HIV envelope (Env) and SIV Gag and administered them intranasally to macaques, adopted by boosting with virus-like particles (VLPs) containing trimeric HIV Env. Moreover, we in contrast the immune responses generated by PIV5-SHIV prime/VLPs enhance routine in naïve vs a management group wherein pre-existing immunity to the PIV5 vector was established.

We display for the primary time that intranasal administration of PIV5-based HIV vaccines is protected, well-tolerated and immunogenic, and that boosting with adjuvanted trimeric Env VLPs enhances humoral and mobile immune responses. The PIV5 prime/VLPs enhance routine induced strong and sturdy systemic and mucosal Env-specific antibody titers with practical actions together with ADCC and neutralization. This routine additionally induced extremely polyfunctional antigen-specific T cell responses. Importantly, we present that diminished responses due to PIV5 pre-existing immunity may be overcome partly with VLP protein boosts.

Overall, these outcomes set up that PIV5-based HIV vaccine candidates are promising and warrant additional investigation together with transferring on to primate problem research. This blended strategies research aimed to consider the feasibility and preliminary efficacy of a totally automated, interactive smartphone-delivered intervention for smoking cessation amongst individuals dwelling with HIV in Cambodia. We used the explanatory sequential design, with a pilot two-group single-blind randomized managed trial (N = 50) adopted by in-depth interviews with all trial individuals. In the trial, individuals had been randomized to Standard Care (SC) or Automated Messaging (AM) group. SC comprised temporary recommendation to give up and self-help supplies.

Exploration of a Sequential Gp140-Gp145 Immunization Regimen with Heterologous Envs to Induce a Protective Cross-Reactive HIV Neutralizing Antibody Response In Non-human Primates

Exploring HIV stigma amongst future healthcare suppliers in Indonesia

Future healthcare professionals are an vital group for interventions to get rid of HIV stigma within the well being workforce. Researchers examined HIV stigma and its relationship with healthcare self-discipline, HIV information, and religiosity amongst nursing, medical, and midwifery college students (N = 505) in three areas of Indonesia. In a multivariable linear mannequin, larger HIV stigma was related with male intercourse, decrease ranges of earnings and HIV information, and better ranges of religiosity. An interplay of healthcare self-discipline and province was additionally important. Medical college students in Jakarta had larger predicted stigma scores in contrast to nursing college students in Jakarta and in contrast to medical college students in different provinces.

Nursing college students in Papua had decrease predicted stigma scores in contrast to medical and midwifery college students in Papua and in contrast to nursing college students elsewhere. Strategies to cut back HIV stigma within the Indonesian well being workforce ought to embrace a robust deal with pre-clinical academic settings and contemplate public nursing establishments as offering attainable greatest apply fashions. Human immunodeficiency virus sort 1 (HIV-1) is principally transmitted by sexual activity, and efficient microbicides stopping HIV-1 transmission are nonetheless required.

Recombinant HIV-1 Envelope, His Tag
7-07590 1000µg Ask for price

HIV-1 Envelope Recombinant
rAP-5337 Inquiry Ask for price

Recombinant HIV-1 Envelope (233)
7-07585 100µg Ask for price

Recombinant HIV-1 Envelope (233)
7-07586 500µg Ask for price

Recombinant HIV-1 Envelope (233)
7-07587 1000µg Ask for price

HIV 1, 2 envelope recombinant antigen. HIV-1 envelope conjugated to HIV-2 envelope peptide.
00175-V 1 MG
EUR 850

HIV 1, 2 envelope recombinant antigen. HIV-1 envelope conjugated to HIV-2 envelope peptide.
00175-V-100ugvial 100ug/vial
EUR 150
Description: HIV 1, 2 envelope recombinant antigen. HIV-1 envelope conjugated to HIV-2 envelope peptide.

HIV-1 Envelope (233), (Recombinant)
22060193-1 100 µg
EUR 264.47

Recombinant HIV-2 Envelope
7-07744 100µg Ask for price

Recombinant HIV-2 Envelope
7-07745 500µg Ask for price

Recombinant HIV-2 Envelope
7-07746 1000µg Ask for price

HIV-2 Envelope Recombinant
rAP-5370 Inquiry Ask for price

HIV 1 envelope recombinant antigen
00176-V-01mg 0,1 mg
EUR 321
Description: HIV 1 envelope recombinant antigen. HIV-1 evnelope protein spanning the C-Terminus of gp 120 and most of gp 41.

HIV 1 envelope recombinant antigen
00176-V-1000ug 1000 ug
EUR 1539
Description: HIV 1 envelope recombinant antigen. HIV-1 evnelope protein spanning the C-Terminus of gp 120 and most of gp 41.

HIV 1, 2 envelope recombinant antigen
00175-V-01mg 0,1 mg
EUR 321
Description: HIV 1, 2 envelope recombinant antigen. HIV-1 envelope conjugated to HIV-2 envelope peptide.

HIV 1, 2 envelope recombinant antigen
00175-V-1000ug 1000 ug
EUR 1539
Description: HIV 1, 2 envelope recombinant antigen. HIV-1 envelope conjugated to HIV-2 envelope peptide.

HIV-1 gp120 MN Envelope Recombinant
rAP-5348 Inquiry Ask for price

HIV-1 gp120 CM Envelope Recombinant
rAP-5374 Inquiry Ask for price

HIV-1 gp120 LAV Envelope Recombinant
rAP-5372 Inquiry Ask for price

Recombinant (E.Coli) HIV-2 Envelope
RP-573 100 ug
EUR 343.2

Recombinant HIV-1 gp 41 Envelope Protein
VAng-0532Lsx-inquire inquire Ask for price
Description: HIV type 1 Glycoprotein 41 Envelope Antigen, recombinant protein from E. coli, MW 146 kDa with Beta-galactosidase (114 kDa), 1.00 mg/mL.

Recombinant HIV-1 Envelope conjugated to HIV-2 gp39
7-07711 100µg Ask for price

Recombinant HIV-1 Envelope conjugated to HIV-2 gp39
7-07712 500µg Ask for price

Recombinant HIV-1 Envelope conjugated to HIV-2 gp39
7-07713 1000µg Ask for price

Recombinant HIV Type-O Envelope
7-07714 100µg Ask for price

Recombinant HIV Type-O Envelope
7-07715 500µg Ask for price

Recombinant HIV Type-O Envelope
7-07716 1000µg Ask for price

HIV-1 Envelope conjugated to HIV-2 gp39 (Recombinant)
22060194-1 100 µg
EUR 264.47

HIV-1 envelope conjugated to HIV-2 gp39 Recombinant
rAP-5362 Inquiry Ask for price

HIV Type-O Envelope (Recombinant)
22060191-1 100 µg
EUR 264.47

Recombinant (E.Coli) HIV-1 Envelope conjugated to HIV-2 gp39
RP-564 100 ug
EUR 343.2

Recombinant 2019-nCoV Envelope Protein (His Tag)
PKSR030488-1mg 1mg
EUR 880
Description: SARS-CoV-2

Recombinant (E.Coli) HIV Type-O Envelope
RP-565 100 ug
EUR 343.2

Recombinant HIV-1 Envelope Protein, Untagged, E.coli-1mg
QP12241-1mg 1mg
EUR 1273.2

Recombinant HIV-1 Envelope Protein, Untagged, E.coli-100ug
QP12241-100ug 100ug
EUR 261.6

Recombinant HIV-1 Envelope Protein, Untagged, E.coli-500ug
QP12241-500ug 500ug
EUR 795.6

Recombinant AcmNPV Envelope glycoprotein gp64(His Tag)
PKSV030117-100ug 100ug
EUR 855
Description: AcMNPV

Recombinant AcmNPV Envelope glycoprotein gp64(His Tag)
PKSV030118-100ug 100ug
EUR 855
Description: AcMNPV

SARS-CoV-2 Envelope Recombinant Protein His Tag
ICOV2ENVRHIS50UG each
EUR 648
Description: SARS-CoV-2 Envelope Recombinant Protein His Tag

Recombinant HIV-2 Envelope Protein, Untagged, E.coli-1mg
QP12267-1mg 1mg
EUR 1273.2

Recombinant HIV-1 (group M, subtype A, isolate 92RW020) Envelope glycoprotein gp160 Protein (gp120 subunit) (His Tag)
PKSV030181-100ug 100ug
EUR 855
Description: HIV

Recombinant HIV-2 Envelope Protein, Untagged, E.coli-100ug
QP12267-100ug 100ug
EUR 261.6

Recombinant HIV-2 Envelope Protein, Untagged, E.coli-500ug
QP12267-500ug 500ug
EUR 795.6

Recombinant ZIKV E / Envelope protein (Domain III, His Tag)
PKSV030265-100ug 100ug
EUR 855
Description: ZIKV

Recombinant HIV HTLV-1 Envelope Protein, Untagged, E.coli-1mg
QP12353-1mg 1mg
EUR 1273.2

Recombinant HIV HTLV-1 Envelope Protein, Untagged, E.coli-100ug
QP12353-100ug 100ug
EUR 261.6

Recombinant HIV HTLV-1 Envelope Protein, Untagged, E.coli-500ug
QP12353-500ug 500ug
EUR 795.6

Recombinant ZIKV (strain Zika SPH2015) Envelope protein ( His Tag)
PKSV030266-100ug 100ug
EUR 855
Description: ZIKV

Recombinant ZIKV E / Envelope protein (Domain I, His & MBP Tag)
PKSV030264-100ug 100ug
EUR 855
Description: ZIKV

Recombinant CHIKV (strain SL-CK1) Envelope 2 Protein (His Tag)
PKSV030119-100ug 100ug
EUR 855
Description: CHIKV

Recombinant Human HIV-1 (group M, subA, HXB2) Envelope gp160 Protein, His-SUMO, E.coli-1mg
QP7356-ec-1mg 1mg
EUR 1958.4

Recombinant HIV Type-O Envelope Protein, Untagged, E.coli-1mg
QP12237-1mg 1mg
EUR 1273.2

Recombinant Human HIV-1 (group M, subA, HXB2) Envelope gp160 Protein, His-SUMO, E.coli-100ug
QP7356-ec-100ug 100ug
EUR 489.6

Recombinant Human HIV-1 (group M, subA, HXB2) Envelope gp160 Protein, His-SUMO, E.coli-10ug
QP7356-ec-10ug 10ug
EUR 240

Recombinant Human HIV-1 (group M, subA, HXB2) Envelope gp160 Protein, His-SUMO, E.coli-200ug
QP7356-ec-200ug 200ug
EUR 760.8

Recombinant Human HIV-1 (group M, subA, HXB2) Envelope gp160 Protein, His-SUMO, E.coli-500ug
QP7356-ec-500ug 500ug
EUR 1272

Recombinant Human HIV-1 (group M, subA, HXB2) Envelope gp160 Protein, His-SUMO, E.coli-50ug
QP7356-ec-50ug 50ug
EUR 315.6

Recombinant YFV Envelope protein [His]
DAGA-3030 0.1 mg
EUR 780

Recombinant HIV Type-O Envelope Protein, Untagged, E.coli-100ug
QP12237-100ug 100ug
EUR 261.6

Recombinant HIV Type-O Envelope Protein, Untagged, E.coli-500ug
QP12237-500ug 500ug
EUR 795.6

Recombinant SARS-CoV-2 envelope Protein with His and Avi Tag
E80005-1 100 ul
EUR 518.1

Recombinant SARS-CoV-2 envelope Protein with His and Avi Tag
E80005 100 µg
EUR 489

Recombinant DENV type 1 Envelope Protein [His]
DAG3058 1 mg
EUR 982.8
Description: Recombinant

Recombinant ZIKV (strain Zika SPH2015) Envelope protein (aa 291-696, His Tag)
PKSV030267-100ug 100ug
EUR 855
Description: ZIKV

Recombinant SIV (isolate F236) envelope glycoprotein gp120 Protein (His Tag)
PKSV030255-100ug 100ug
EUR 855
Description: SIV

Recombinant WNV (lineage 1, strain NY99) E / Envelope Protein (Domain III, His Tag)
PKSV030259-100ug 100ug
EUR 855
Description: WNV

Recombinant WNV (lineage 1, strain NY99) E / Envelope Protein (Domain III, His Tag)
PKSV030260-100ug 100ug
EUR 855
Description: WNV

Recombinant ZIKV (strain Zika SPH2015) Envelope protein (Domain III, His Tag)
PKSV030270-100ug 100ug
EUR 855
Description: ZIKV

Recombinant ZIKV (strain Zika SPH2015) Envelope protein (Domain III, His Tag)
PKSV030271-100ug 100ug
EUR 855
Description: ZIKV

Recombinant HCV (serotype 1b, isolate HC-J4) Envelope / E2 Protein (His Tag)
PKSV030176-100ug 100ug
EUR 855
Description: HCV

Recombinant DENV (type 1, strain US/Hawaii/1944) E / Envelope Protein (Domain III, His Tag)
PKSV030123-100ug 100ug
EUR 855
Description: DENV

HTLV-1 Envelope (Recombinant)
22060224-1 100 µg
EUR 264.47

Recombinant HTLV-1 Envelope
7-07753 100µg Ask for price

Recombinant HTLV-1 Envelope
7-07754 500µg Ask for price

Recombinant HTLV-1 Envelope
7-07755 1000µg Ask for price

HTLV-1 Envelope Recombinant
rAP-5382 Inquiry Ask for price

Recombinant (E.Coli) HIV-1 Envelope (233-aa, HIVgp41+gp120-beta-Gal fusion protein, 27.2 kda)
RP-533 100 ug
EUR 343.2

SARS-CoV-2 (COVID-19) Envelope Recombinant Protein N-terminal His Tag and Avi Tag
ICOV2ETRNTHISAVI100UG each
EUR 867
Description: SARS-CoV-2 (COVID-19) Envelope Recombinant Protein N-terminal His Tag and Avi Tag

Dengue Envelope - 1 & 3 (Recombinant)
22060048-1 100 µg
EUR 200.4

Recombinant SARS-CoV-2 Envelope Protein [His]
DAGC165 100 µg
EUR 649.69
Description: Recombinant

Recombinant DENV Envelope Protein [His] (4.10 mg/mL)
VAng-Wyb8604-inquire inquire Ask for price
Description: Dengue virus Type 1 Envelope Protein (aa 281-675), recombinant protein from Drosophila S2, 4.10 mg/mL.

Recombinant DENV Envelope Protein [His] (2.1 mg/mL)
VAng-Wyb8605-inquire inquire Ask for price
Description: Dengue virus Type 1 Envelope Protein (EP) (aa 281-675), recombinant protein from Drosophila, 2.1 mg/mL.

Recombinant DENV (type 4, strain Philippines/H241/1956) E / Envelope Protein (ECD, His Tag)
PKSV030130-100ug 100ug
EUR 855
Description: DENV

Recombinant SIV (isolate SIVmac251v31523ru28) envelope glycoprotein gp120 Protein (His Tag)
PKSV030256-100ug 100ug
EUR 855
Description: SIV

Zika Envelope Recombinant
rAP-5506 Inquiry Ask for price

Recombinant (E.Coli) HTLV-1 Envelope
RP-539 100 ug
EUR 343.2

Recombinant Zika Envelope Protein, His, E.coli-1mg
QP13997-HIS-1mg 1mg
EUR 1513.2

Recombinant Zika Envelope Protein, His, E.coli-2ug
QP13997-HIS-2ug 2ug
EUR 186

HIV-1 Envelope
hiv-101 100µg
EUR 165
Description: Recombinant HIV-1 Envelope (233)

HIV-1 Envelope
PR-1200 100µg
EUR 300.7
Description: recombinant, E. coli

HIV 1 envelope recombinant antigen. HIV-1 evnelope protein spanning the C-Terminus of gp 120 and most of gp 41.
00176-V 1 MG
EUR 850

HIV 1 envelope recombinant antigen. HIV-1 evnelope protein spanning the C-Terminus of gp 120 and most of gp 41.
00176-V-100ugvial 100ug/vial
EUR 150
Description: HIV 1 envelope recombinant antigen. HIV-1 evnelope protein spanning the C-Terminus of gp 120 and most of gp 41.

Recombinant Zika Envelope Protein, His, E.coli-10ug
QP13997-HIS-10ug 10ug
EUR 241.2

Recombinant Zika Envelope Protein, His, E.coli-50ug
QP13997-HIS-50ug 50ug
EUR 654

Recombinant Bourbon virus envelope glycoprotein [His]
DAGA-3104 100ug
EUR 1326

Recombinant Zika Envelope Protein, His, E.coli-100ug
QP13997-HIS-100ug 100ug
EUR 261.6

Recombinant Zika Envelope Protein, His, E.coli-500ug
QP13997-HIS-500ug 500ug
EUR 795.6

Recombinant Zika Envelope N Protein, His, E.coli-1mg
QP14000-1mg 1mg
EUR 1513.2

Bacteria-Derived SARS-CoV-2 (COVID-19) Envelope Recombinant Protein GST Tag His Tag Lyophilized
IBCTCOV2ETRGSTHISLY100UG each
EUR 851
Description: Bacteria-Derived SARS-CoV-2 (COVID-19) Envelope Recombinant Protein GST Tag His Tag Lyophilized

Recombinant DENV premembrane (prM) Envelope Protein [His]
VAng-Wyb8600-inquire inquire Ask for price
Description: Dengue virus Type 2 premembrane (prM) Envelope Protein, recombinant protein from Insect Cells, 4.0 mg/mL.

HIV type 1 Envelope protein [His]
DAG1511 100 µg
EUR 774

Recombinant Zika Envelope N Protein, His, E.coli-100ug
QP14000-100ug 100ug
EUR 261.6

Recombinant Zika Envelope N Protein, His, E.coli-500ug
QP14000-500ug 500ug
EUR 795.6

Zika Envelope Recombinant, sf9
rAP-5510 Inquiry Ask for price

SARS-CoV-2 Envelope Recombinant Protein N-BBP-6His Tag
ICOV2ENVRNBBP6HIS100UG each
EUR 519
Description: SARS-CoV-2 Envelope Recombinant Protein N-BBP-6His Tag

Recombinant Human Envelope glycoprotein 1, His-SUMO, E.coli-1mg
QP7363-ec-1mg 1mg
EUR 1958.4

Recombinant Human Envelope glycoprotein 1, His-SUMO, E.coli-1mg
QP7033-ec-1mg 1mg
EUR 1958.4

Recombinant Human Envelope glycoprotein 1, His-SUMO, E.coli-10ug
QP7363-ec-10ug 10ug
EUR 240

Recombinant Human Envelope glycoprotein 1, His-SUMO, E.coli-50ug
QP7363-ec-50ug 50ug
EUR 315.6

Recombinant Human Envelope glycoprotein 1, His-SUMO, E.coli-10ug
QP7033-ec-10ug 10ug
EUR 240

Recombinant Human Envelope glycoprotein 1, His-SUMO, E.coli-50ug
QP7033-ec-50ug 50ug
EUR 315.6

Recombinant Cytomegalovirus Envelope glycoprotein 1, His, Yeast-1mg
QP7456-ye-1mg 1mg
EUR 3296.4

Recombinant Envelope Protein (E)
RPX170Ge01 10ug
EUR 159

Recombinant Envelope Protein (E)
4-RPX170Ge01
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
Description: Recombinant Pan-species Envelope Protein expressed in: E.coli

Recombinant Envelope Protein (E)
RPU56063-100ug 100ug
EUR 490.6

Recombinant Envelope Protein (E)
RPU56063-1mg 1mg
EUR 2483

Recombinant Envelope Protein (E)
RPU56063-50ug 50ug
EUR 382.1

Recombinant DENV (type 2, strain New Guinea C/PUO-218 hybrid) E / Envelope Protein (His Tag)
PKSV030128-100ug 100ug
EUR 855
Description: DENV

Recombinant Human Envelope glycoprotein 1, His-SUMO, E.coli-100ug
QP7363-ec-100ug 100ug
EUR 489.6

Recombinant Human Envelope glycoprotein 1, His-SUMO, E.coli-200ug
QP7363-ec-200ug 200ug
EUR 760.8

Recombinant Human Envelope glycoprotein 1, His-SUMO, E.coli-500ug
QP7363-ec-500ug 500ug
EUR 1272

Recombinant Human Envelope glycoprotein 1, His-SUMO, E.coli-100ug
QP7033-ec-100ug 100ug
EUR 489.6

Recombinant Human Envelope glycoprotein 1, His-SUMO, E.coli-200ug
QP7033-ec-200ug 200ug
EUR 760.8

Recombinant Human Envelope glycoprotein 1, His-SUMO, E.coli-500ug
QP7033-ec-500ug 500ug
EUR 1272

Recombinant HCV Envelope Glycoprotein E1 / HCV-E1 (subtype 1b, strain HC-J4) Protein (His Tag)
PKSV030180-100ug 100ug
EUR 855
Description: HCV

Recombinant Dengue Virus Dengue Envelope-1 & 3 Protein, His, E.coli-1mg
QP11620-1mg 1mg
EUR 1513.2

Recombinant Dengue Virus Dengue Envelope-1 & 4 Protein, His, E.coli-1mg
QP11621-1mg 1mg
EUR 1513.2

Recombinant Cytomegalovirus Envelope glycoprotein 1, His, Yeast-100ug
QP7456-ye-100ug 100ug
EUR 979.2

Recombinant Cytomegalovirus Envelope glycoprotein 1, His, Yeast-10ug
QP7456-ye-10ug 10ug
EUR 445.2

Recombinant Cytomegalovirus Envelope glycoprotein 1, His, Yeast-200ug
QP7456-ye-200ug 200ug
EUR 1555.2

Recombinant Cytomegalovirus Envelope glycoprotein 1, His, Yeast-500ug
QP7456-ye-500ug 500ug
EUR 2164.8

Recombinant Cytomegalovirus Envelope glycoprotein 1, His, Yeast-50ug
QP7456-ye-50ug 50ug
EUR 598.8

Recombinant Dengue Virus Subtype-2 Envelope Protein [His]
DAG479 500 ug
EUR 1115.63
Description: Recombinant

Zika Envelope Recombinant Protein
PROTQ83884 Regular: 0.5mg
EUR 945.6
Description: The E.Coli derived Recombinant Zika Envelope protein (250-410 a.a., Strain: ZikaSPH2015) having an Mw of 19kDa is designed with minimal level cross-reaction to other Flavivirus such as dengue and West Nile viruses. ;The Zika Envelope protein is fused to a 6xHis tag at C-terminus and purified by proprietary chromatographic technique.

Recombinant Zika Envelope Protein
P1063-10 each
EUR 189.6

Recombinant Zika Envelope Protein
P1063-50 each
EUR 366

Recombinant DENV Envelope Protein
VAng-Wyb8598-inquire inquire Ask for price
Description: Dengue virus Type 2 Envelope Protein (aa 281-675), recombinant protein from Drosophila S2, 4.32 mg/mL.

Recombinant Dengue Virus Dengue Envelope-1 & 3 Protein, His, E.coli-100ug
QP11620-100ug 100ug
EUR 261.6

Recombinant Dengue Virus Dengue Envelope-1 & 3 Protein, His, E.coli-500ug
QP11620-500ug 500ug
EUR 795.6

Recombinant Dengue Virus Dengue Envelope-1 & 4 Protein, His, E.coli-100ug
QP11621-100ug 100ug
EUR 261.6

Recombinant Dengue Virus Dengue Envelope-1 & 4 Protein, His, E.coli-500ug
QP11621-500ug 500ug
EUR 795.6

Recombinant Dengue Virus Dengue Envelope-1 15kDa Protein, His, E.coli-1mg
QP11622-1mg 1mg
EUR 1513.2

Recombinant Dengue Virus Dengue Envelope-1 22kDa Protein, His, E.coli-1mg
QP11623-1mg 1mg
EUR 1513.2

Recombinant Dengue Virus Dengue Envelope-1 32kDa Protein, His, E.coli-1mg
QP11624-1mg 1mg
EUR 1513.2

Recombinant Dengue Virus Dengue Envelope-1 45kDa Protein, His, E.coli-1mg
QP11625-1mg 1mg
EUR 1513.2

Recombinant Zika Envelope F. Length Protein, His, E.coli-1mg
QP13999-1mg 1mg
EUR 1513.2

Recombinant DENV (type 2, strain New Guinea C/PUO-218 hybrid) E / Envelope Protein (ECD, His Tag)
PKSV030127-100ug 100ug
EUR 855
Description: DENV

West Nile Virus Envelope Recombinant Protein 6-his liquid
IWNVWNVENVR6HIS10UG each
EUR 851
Description: West Nile Virus Envelope Recombinant Protein 6-his liquid

Recombinant Zika Envelope Domain-3 Protein, His, E.coli-1mg
QP13998-1mg 1mg
EUR 795.6

Recombinant Dengue Virus Dengue Envelope-1 15kDa Protein, His, E.coli-100ug
QP11622-100ug 100ug
EUR 261.6

Recombinant Dengue Virus Dengue Envelope-1 15kDa Protein, His, E.coli-500ug
QP11622-500ug 500ug
EUR 795.6

Recombinant Dengue Virus Dengue Envelope-1 22kDa Protein, His, E.coli-100ug
QP11623-100ug 100ug
EUR 261.6

Amphibian pores and skin is a wealthy supply of protection peptides with antiviral exercise. Here, we characterised a lectin-like peptide, fejerlectin (RLCYMVLPCP), remoted from the pores and skin of the frog Fejervarya limnocharis. Fejerlectin confirmed important hemagglutination and d-(+)-galacturonic acid-binding actions. Furthermore, fejerlectin suppressed the early entry of HIV-1 into goal cells by binding to the N-terminal heptad repeat of HIV-1 gp41 and stopping 6-HB formation and Env-mediated membrane fusion. Fejerlectin is the smallest lectin-like peptide recognized to date and represents a new and promising platform for anti-HIV-1 drug growth.